EUCTR2007-001451-19-IT进行中（未招募）不适用
A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-center Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder. - SCORPIO
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 2,160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion criteria at Visit 1/screening
- •1. Male or female subject aged ≥ 18 years.
- •2. Institutional Review Board (IRB)-/Independent Ethics Committee
- •(IEC)-approved written Informed Consent and privacy language as per
- •national regulations is obtained from the subject or legally authorized
- •representative (prior to any study-related procedures; including
- •withdrawal of prohibited medication, if applicable).
- •3. Subject is willing and able to complete the micturition diary and
- •questionnaires correctly.
- •4. Subject has symptoms of overactive bladder (urinary frequency and
- •urgency with or without urge incontinence) for ≥ 3 months.
- •Inclusion criteria at Visit 2/baseline
- •5. Subject experiences frequency of micturition on average ≥ 8 times per
- •24-hour period during the 3-day micturition diary period.
- •6. Subject must experience at least 3 episodes of urgency (grade 3 or 4)
- •with or without incontinence, during the 3-day micturition diary period.
- •7. Subject still fulfills all inclusion criteria and none of the exclusion
- •criteria from Visit 1.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion Criteria at Visit 1/screening
- •1. Subject is breastfeeding, pregnant, intends to become pregnant during
- •the study, or of childbearing potential, sexually active and not practicing
- •a highly reliable method of birth control (these are methods with a
- •failure quotient of <1% per year such as hormonal implants, injectable
- •contraceptives, oral contraceptives of combination type, intra-uterine
- •pessaries restricted to hormone contraceptive coil, sexual abstinence or
- •vasectomy of the partner). The pregnancy test (β-HCG in serum) at Visit
- •1 needs to be negative in women of childbearing potential.
- •2. Subject has clinically significant bladder outflow obstruction at risk of
- •urinary retention (at the discretion of the investigator).
- •3. Subject has significant stress incontinence or mixed stress/urge
- •incontinence where stress is the predominant factor as determined by the
- •investigator (for female subjects confirmed by a cough provocation test
- •Appendix 4).
- •4. Subject has an indwelling catheter or practices intermittent self catheterization.
- •5. Subject has diabetic neuropathy.
- •6. Subject has evidence of a symptomatic urinary tract infection, chronic
- •inflammation such as interstitial cystitis, bladder stones, previous pelvic
- •radiation therapy or previous or current malignant disease of the pelvic
- •7. Subject has uncontrolled narrow angle glaucoma, urinary or gastric
- •retention, severe colitis ulcerosa, toxic megacolon, myasthenia gravis or
- •any other medical condition which in the opinion of the investigator
- •makes the use of anticholinergics contraindicated.
- •8. Subject receives non-drug treatment including electro-stimulation
- •therapy (a bladder training program or pelvic floor exercises which
- •started more than 30 days prior to entry into the study can be continued).
- •9. Subject is using medications intended to treat OAB or prohibited
- •medications listed in Appendix 1, Part A. Subject is excluded if using
- •restricted medications (Appendix 1, Part B) and conditions specified in
- •Appendix 1, Part B are not met.
- •10. Subject has a known or suspected hypersensitivity to tolterodine, other
- •anticholinergics, YM178, other ß-AR agonists, or lactose or any of the
- •other inactive ingredients.
- •11. Subject has any clinically significant condition, which in the opinion of
- •the investigator makes the subject unsuitable for the study.
- •12. Subject has been treated with any investigational drug or device within
- •30 days (90 days in the UK) prior to Visit 1/screening.
- •13. Subject is an employee of the Astellas Group, third parties associated
- •with the study, or the clinical study site team.
- •Exclusion criteria at Visit 2/baseline
- •14. Subject had an average total daily urine volume > 3000 mL as recorded
- •in the 3-day micturition diary period.
- •15. Subject has - in the opinion of the investigator - clinically significant
- •increases in laboratory values as assessed in Visit 1 samples (e.g. serum
- •creatinine >150 umol/L, AST and/or ALT > 2x upper limit of normal
- •range (ULN), or γ-GT > 3x ULN).
- •16. Subject has an abnormal ECG, which in the opinion of the investigator
- •makes the subject unsuitable for the study.
研究者
相似试验
进行中（未招募）
1 期
A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder - SCORPIOEUCTR2007-001451-19-ISAstellas Pharma Europe B.V.2,160
进行中（未招募）
不适用
A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-Center Dose Ranging Study with the Beta-3 AGONist YM178 in Patients with Symptomatic Overactive Bladder (DRAGON) - DRAGOOveractive bladderMedDRA version: 8.1Level: LLTClassification code 10059617EUCTR2005-002256-17-DEAstellas Pharma Europe B.V.1,070
进行中（未招募）
1 期
A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder - SCORPIOSymptoms of Overactive BladderMedDRA version: 9.1Level: LLTClassification code 10059617Term: Overactive bladderEUCTR2007-001451-19-IEAstellas Pharma Europe B.V.2,160
进行中（未招募）
不适用
A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder - SCORPIOSymptoms of Overactive BladderMedDRA version: 9.1Level: LLTClassification code 10059617Term: Overactive bladderEUCTR2007-001451-19-FIAstellas Pharma Europe B.V.2,160
进行中（未招募）
不适用
A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder - SCORPIOEUCTR2007-001451-19-NLAstellas Pharma Europe B.V.2,160